Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 8/20 | 0.66 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.62 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CDK14 | O94921 | 3/20 | 0.37 |
| ▸ | CCNY | Q8ND76 | 3/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206103 | 1.00 | IRAK1 (0.66) | IRAK1MAP3K19IRAK4NPC1ALDH1A1 | |
| SCHEMBL23860749 | 0.91 | IRAK1 (0.63) | IRAK1MAP3K19IRAK4NPC1ALDH1A1 | |
| SCHEMBL20206130 | 0.91 | IRAK1 (0.63) | IRAK1MAP3K19IRAK4NPC1ALDH1A1 | |
| SCHEMBL30165336 | 0.91 | IRAK1 (0.63) | IRAK1MAP3K19IRAK4NPC1ALDH1A1 | |
| SCHEMBL20206223 | 0.91 | IRAK1 (0.63) | IRAK1MAP3K19IRAK4NPC1ALDH1A1 | |
| SCHEMBL20206097 | 0.90 | IRAK1 (0.76) | IRAK1MAP3K19IRAK4CDK14CCNY | |
| SCHEMBL21328552 | 0.90 | IRAK1 (0.76) | IRAK1MAP3K19IRAK4CDK14CCNY | |
| SCHEMBL20206142 | 0.84 | IRAK1 (0.61) | IRAK1MAP3K19IRAK4NPC1ALDH1A1 | |
| SCHEMBL20206104 | 0.84 | IRAK1 (0.59) | IRAK1MAP3K19IRAK4NPC1ALDH1A1 | |
| SCHEMBL20206098 | 0.83 | IRAK1 (0.71) | IRAK1MAP3K19IRAK4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544970-B1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885IRAK4 2/4885 |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885IRAK4 2/4885 |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885IRAK4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.